Amgen Ireland

Milestones as listed on amgen.ie, amgen.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Leadership as listed on amgen.ie, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Products and services as listed on amgen.ie, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Sites as listed on amgen.ie, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for Amgen Ireland: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 3 Oct 2026.

Clinical trials 97 in our ClinicalTrials.gov registers · 11 in the EU register

Showing 10 of 97, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 1 registry name

Drugs in these trials 61 compounds

EU trials register (CTIS) 11 authorised or ongoing · 1 in Ireland

• A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)2025-520554-11-00 · Phase III · Authorised · site in Ireland
• Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age with Immunoglobulin G4 related Disease (IgG4-RD)2025-520988-41-00 · Phase II · Ongoing
• Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment with Romosozumab in Children and Adolescents with Osteogenesis Imperfecta2023-503293-21-00 · Phase III · Ongoing
• A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight2026-525408-82-00 · Phase III · Authorised
• A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus2025-524788-19-00 · Phase III · Authorised
• A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study Of Inebilizumab In Participants With Autoimmune Hepatitis2025-522393-37-00 · Phase III · Authorised
• A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Adults With Previously Untreated Primary Immune Thrombocytopenia (ITP)2026-525454-11-00 · Phase III · Authorised
• A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants with Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)2025-521671-31-00 · Phase I/II · Authorised

Medicine shortages 3 in the FDA list

• Glycerol Phenylbutyrate Oral LiquidUS (FDA) · resolved · updated 1 Sep 2026
• Ivabradine Hydrochloride TabletUS (FDA) · resolved · updated 24 Mar 2026
• Ivabradine SolutionUS (FDA) · resolved · updated 24 Mar 2026

A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.

NICE technology appraisals 22 of its medicines · 22 current

• Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatmentsNICE TA1091 · Not recommended · 20 Aug 2025
• Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemiaNICE TA1049 · Optimised · 26 Mar 2025
• Romosozumab for treating severe osteoporosisNICE TA791 · Optimised · 25 May 2022
• Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancerNICE TA781 · Recommended (Cancer Drugs Fund) · 30 Mar 2022
• Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)NICE TA686 · Terminated (no company submission) · 31 Mar 2021
• Erenumab for preventing migraineNICE TA682 · Optimised · 10 Mar 2021
• Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activityNICE TA589 · Optimised · 24 Jul 2019
• Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)NICE TA549 · Terminated (no company submission) · 5 Dec 2018

Appraisals of medicines whose first EU or US authorisation was held by this company, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (Amgen Ireland): founded 1980, headquarters Thousand Oaks, website amgen.com. Wikidata Q470517 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.

How this is matched: register records are linked to this page by the organisation name they carry, here Amgen; Amgen Inc.; AMGEN; AMGEN INC. Spot a wrong match? Tell us.

Group figures for Amgen Inc., the parent company. From the annual reports Amgen Inc. files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.

R&D is shown as tagged in the filing, which for this company can exclude acquired in-process R&D. Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.

Companies registered in Ireland 4 active in the CRO register

From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Amgen Inc. as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.